# Sol-Gel Technologies, Ltd.: Phase 3 study completed, 113 enrolled (Gorlin Syndrome)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Sol-Gel Technologies, Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome |
| NCT ID | NCT06050122 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Gorlin Syndrome |
| Intervention types | drug |
| Target enrollment | 113 |
| Site countries | United States, France, Germany, Italy, Netherlands, Spain, United Kingdom |
| Posted | 2023-09-22 |
| Planned start | 2024-03-17 |
| Event | Completed |
| Event date | 2026-09-14 |
| Last update posted | 2026-09-18 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 113 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06050122). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.